公开(公告)号：US09914706B2

公开(公告)日：2018-03-13

申请号：US15101126

申请日：2014-12-10

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Donald J. Skalitzky ,  Clarke B. Taylor

IPC: C07D231/38 ,  C07D405/04 ,  C07D401/04 ,  C07D401/08 ,  C07D403/04 ,  C07D405/08

CPC classification number: C07D231/38 ,  C07D401/04 ,  C07D401/08 ,  C07D403/04 ,  C07D405/04 ,  C07D405/08

Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

公开(公告)号：US20190276447A1

公开(公告)日：2019-09-12

申请号：US16275426

申请日：2019-02-14

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Fernando Padilla ,  Donald J. Skalitzky ,  Peter L. Toogood ,  Chad A. VanHuis

IPC: C07D417/14 ,  C07D417/12 ,  C07D471/04 ,  C07F9/6558

Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.

公开(公告)号：US20180222867A1

公开(公告)日：2018-08-09

申请号：US15896378

申请日：2018-02-14

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Donald J. Skalitzky ,  Clarke B. Taylor

IPC: C07D231/38 ,  C07D405/04 ,  C07D401/08 ,  C07D403/04 ,  C07D405/08 ,  C07D401/04

CPC classification number: C07D231/38 ,  C07D401/04 ,  C07D401/08 ,  C07D403/04 ,  C07D405/04 ,  C07D405/08

Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

公开(公告)号：US20160304465A1

公开(公告)日：2016-10-20

申请号：US15101129

申请日：2014-12-10

Applicant: LYCERA CORPORATION

Inventor： Donald J. Skalitzky ,  Chad A. VanHuis

IPC: C07D231/38

CPC classification number: C07D231/38

Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

Abstract translation: 本发明提供了抑制F1Fo-ATP酶的吡唑基胍化合物，以及使用吡唑基胍化合物作为治疗药物治疗医学病症如免疫疾病，炎性病症或癌症的方法。

公开(公告)号：US09815791B2

公开(公告)日：2017-11-14

申请号：US15101129

申请日：2014-12-10

Applicant: Lycera Corporation

Inventor： Donald J. Skalitzky ,  Chad A. VanHuis

IPC: C07D231/38 ,  A61K31/415

CPC classification number: C07D231/38

Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

公开(公告)号：US10556898B2

公开(公告)日：2020-02-11

申请号：US16275426

申请日：2019-02-14

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Fernando Padilla ,  Donald J. Skalitzky ,  Peter L. Toogood ,  Chad A. VanHuis

IPC: C07D417/12 ,  C07D417/14 ,  C07F9/6558 ,  C07D471/04

Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.

公开(公告)号：US10392350B2

公开(公告)日：2019-08-27

申请号：US15896378

申请日：2018-02-14

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Donald J. Skalitzky ,  Clarke B. Taylor

IPC: C07D231/38 ,  C07D405/04 ,  C07D401/08 ,  C07D403/04 ,  C07D405/08 ,  C07D401/04

Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

公开(公告)号：US10189777B2

公开(公告)日：2019-01-29

申请号：US15308734

申请日：2015-05-05

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Donald J. Skalitzky ,  Clarke B. Taylor ,  Chad A. Van Huis

IPC: C07C311/21 ,  C07C317/18 ,  C07D207/09 ,  C07D209/14 ,  C07D231/08 ,  C07D231/20 ,  C07D231/56 ,  C07D263/58 ,  C07D309/08

Abstract: The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.

公开(公告)号：US09920012B2

公开(公告)日：2018-03-20

申请号：US14403779

申请日：2013-06-07

Applicant: Lycera Corporation

Inventor： Alexander R. Hurd ,  Donald J. Skalitzky ,  Clarke B. Taylor ,  Peter L. Toogood ,  Chad A. Van Huis

IPC: C07D231/56 ,  C07D405/12 ,  C07D401/12 ,  C07D413/12 ,  C07D471/04

CPC classification number: C07D231/56 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04

Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

公开(公告)号：US20170190659A1

公开(公告)日：2017-07-06

申请号：US15308734

申请日：2015-05-05

Applicant: Lycera Corporation

Inventor： Thomas D. Aicher ,  Donald J. Skalitzky ,  Clarke B. Taylor ,  Chad A. Van Huis

IPC: C07C311/21 ,  C07C317/18 ,  C07D309/08 ,  C07D231/20 ,  C07D263/58 ,  C07D207/09 ,  C07D231/56 ,  C07D231/08 ,  C07D209/14

CPC classification number: C07C311/21 ,  C07C317/18 ,  C07C2601/14 ,  C07C2602/08 ,  C07D207/09 ,  C07D209/14 ,  C07D231/08 ,  C07D231/20 ,  C07D231/56 ,  C07D263/58 ,  C07D309/08

Abstract: The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.